RRP9

Across TCGA pan-cancer cohorts, RRP9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RRP9 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RRP9 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RRP9 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where RRP9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.352	0.835	<.001	44	view →
PDAC	DFS	Median	III,IV	0.214	0.518	<.001	34	view →
LUAD	DFS	Tertile	III,IV	0.670	0.210	.015	9	view →
LSCC	DFS	Quartile	II,III,IV	0.929	0.544	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RRP9–CCRCC (OS)

Open the CCRCC breakdown →